

WHAT IS CLAIMED IS:

1. An antifungal peptide having from seven to twelve amino acids comprising:

5 (a) a core sequence of amino acids selected from the group consisting of LIQL, IQLF, WLIQL, LIQLF and WLIQLF; and

(b) one or more cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion of the core sequence.

10

2. An antifungal peptide having from seven to nine amino acids comprising:

(a) a core sequence of amino acids selected from the group consisting of LIQL and IQLF; and

15 (b) at least two cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion of the core sequence.

3. An antifungal peptide having from eight to ten amino acids comprising:

20 (a) a core sequence of amino acids selected from the group consisting of LIQLF and WLIQLF; and

(b) at least two cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy
25 terminal portion of the core sequence.

4. An antifungal peptide having from nine to twelve amino acids comprising:

(a) a core sequence of amino acids selected from the group consisting of
30 WLIQLF; and

(b) at least three cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion of the core sequence.

5 5. An antifungal peptide according to claim 1, 2, 3 or 4 selected from the group consisting of the peptides of SEQ ID NOS: 118-137 (XMP.285-304), 140-144 (XMP.307-311), 155-160 (XMP.322-327), 166-170 (XMP.335-339), 174-177 (XMP.343-346), 179-184 (XMP.348-353), 186 (XMP.355) and 188-190 (XMP.357-359).

10

6. An antifungal peptide according to claim 1, 2, 3 or 4 having one or more D-isomer amino acids.

7. An antifungal peptide according to claim 6 selected from the group
15 consisting of the peptides of SEQ ID NOS: 164 (XMP.333), 165 (XMP.334), 173 (XMP.342), 194 (XMP.363) and 196 (XMP.365).

8. An antifungal peptide according to claim 6 wherein said core sequence amino acids comprise D-isomer amino acids in reverse sequence order.

20

9. An antifungal peptide according to claim 8 having the amino acid sequence set out in SEQ ID NOS: 163 (XMP.332) and 198 (XMP.367).

10. An antifungal peptide according to claim 1, 2, 3 or 4 wherein the
25 amino terminal amino acid residue is acetylated.

11. An antifungal peptide according to claim 10 selected from the group consisting of the peptides of SEQ ID NOS: 162 (XMP.331), 185 (XMP.354), 187 (XMP.356), 195 (XMP.364), 199 (XMP.368) and 204 (XMP.373).

30

12. A cyclic antifungal peptide according to claim 1, 3 or 4.

13. A cyclic antifungal peptide according to claim 3 selected from the group consisting of SEQ ID NOS: 191-193 (XMP.360-362).

5

14. An antifungal peptide selected from the group consisting of peptides of SEQ ID NOS: 1 (XMP.5), 2-4 (XMP.11-13), 5 (XMP.29), 20 (XMP.55), 56 (XMP.137), 79 (XMP.235), 111-115 (XMP.271-275), 117 (XMP.284), 132 (XMP.299), 138-139 (XMP.305-306), 145-154 (XMP.312-321), 200-203 (XMP.369-372), BPI residues 145-159 and 149-163 of SEQ ID NO: 206 and 171-172 (XMP.340-341).

10

15. A pharmaceutical composition comprising an antifungal peptide according to any of claims 1 through 14 and a pharmaceutically acceptable diluent, adjuvant or carrier.

15

16. An *in vitro* method for killing or inhibiting replication of fungi comprising contacting the fungi with an antifungal peptide according to any one of claims 1 through 14.

20

17. A method of treating fungal infections comprising administering to a subject suffering from a fungal infection a therapeutically effective amount of a peptide according to any of claims 1 through 14.

25

18. A method according to claim 17 wherein the fungal infection involves a fungal species selected from the group consisting of *Candida*, *Aspergillus* and *Cryptococcus* species.

19. A method according to claim 18 wherein the *Candida* species is selected from the group consisting of *C. albicans*, *C. glabrata*, *C. krusei*, *C. lusitaniae*, *C. parapsilosis* and *C. tropicalis*.

5 20. A method according to claim 18 wherein the peptide is administered topically, intravenously, orally or as an aerosol.

21. A method according to claim 17 comprising the additional step of administering a non-peptide anti-fungal agent.

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500